Vanderbilt-ingram Cancer Center
Clinical trials sponsored by Vanderbilt-ingram Cancer Center, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can freezing kill lung cancer? new study tests cryodevitalization Results expected Dec 2026 (estimated)
- AI could help avoid unnecessary lung procedures Results expected Jan 2027 (estimated)
- 4,000 volunteers help scientists hunt lung cancer clues in body fluids Results expected Jan 2027 (estimated)
- New drug combo aims to outsmart resistant leukemia Results expected Feb 2027 (estimated)
- Scientists create massive breast tissue library to unlock cancer secrets Results expected Mar 2027 (estimated)
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThis trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…
Phase 2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Glowing cancer cells: a new way to see tumors during surgery?
Diagnosis Not yet recruitingThis trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled fo…
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Can a pill rewrite the genetic story of resistant kidney cancer?
Knowledge-focused Not yet recruitingThis pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor…
Early phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can a glowing drug light up head and neck tumors?
Knowledge-focused Not yet recruitingThis early-phase trial is testing whether injecting a fluorescently labeled version of the immunotherapy drug nivolumab directly into head and neck tumors is safe and helps visualize the tumor and nearby lymph nodes during surgery. Adults with head and neck squamous cell carcinom…
Early phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC